Nan Du

No. 51 Fucheng Road
Beijing, 100191, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer.

Hematological biomarkers for predicting pathologic response to neoadjuvant immunochemotherapy and cycle optimization in locally advanced gastric cancer.

Journal: Frontiers in immunology

Published: January 25, 2026

Development of a Machine Learning-Based Predictive Model for Anastomotic Leakage Following Gastric Cancer Surgery.

Development of a Machine Learning-Based Predictive Model for Anastomotic Leakage Following Gastric Cancer Surgery.

Journal: The American surgeon

Published: October 23, 2025

Alcohol-induced and ion-mediated strategy for flexible polysaccharide-based hydrogels with superior evaporative cooling performance.

Alcohol-induced and ion-mediated strategy for flexible polysaccharide-based hydrogels with superior evaporative cooling performance.

Journal: Carbohydrate polymers

Published: July 29, 2025

Exploring the role of LOX family in glioma progression and immune modulation.

Exploring the role of LOX family in glioma progression and immune modulation.

Journal: Frontiers in immunology

Published: October 16, 2024

Spermine Synthase : A Potential Prognostic Marker for Lower-Grade Gliomas.

Spermine Synthase : A Potential Prognostic Marker for Lower-Grade Gliomas.

Journal: Journal of Korean Neurosurgical Society

Published: April 08, 2024

Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.

Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.

Journal: Journal for immunotherapy of cancer

Published: November 10, 2023

Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.

Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: July 21, 2022

Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202).

Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202).

Journal: Journal of gastrointestinal oncology

Published: July 05, 2022

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study.

The efficacy of immune checkpoint inhibitors in advanced EGFR-Mutated non-small cell lung cancer after resistance to EGFR-TKIs: Real-World evidence from a multicenter retrospective study.

Journal: Frontiers in immunology

Published: June 22, 2022

Macrophages promote growth, migration and epithelial-mesenchymal transition of renal cell carcinoma by regulating GSDMD/IL-1β axis.

Macrophages promote growth, migration and epithelial-mesenchymal transition of renal cell carcinoma by regulating GSDMD/IL-1β axis.

Journal: Cytokine

Published: June 15, 2022

Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence.

Knockdown of LMNB1 Inhibits the Proliferation of Lung Adenocarcinoma Cells by Inducing DNA Damage and Cell Senescence.

Journal: Frontiers in oncology

Published: April 06, 2022

LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1.

LINC00244 suppresses cell growth and metastasis in hepatocellular carcinoma by downregulating programmed cell death ligand 1.

Journal: Bioengineered

Published: March 10, 2022

Showing 1-12 of 68

Last Updated: 09/26/2026